LATE-BREAKING ABSTRACT: A randomised, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 on moderate persistent asthma

N. B. Barnes, I. P. Pavord, A. C. Chuchalin, J. B. Bell, M. H. Hunter, M. P. Payton, L. P. C. Pearce Collins, R. P. Pettipher, J. S. Steiner, M. P. Perkins (London, Leicester, Oxford, United Kingdom; Moscow, Russian Federation)

Source: Annual Congress 2009 - Novel approaches in asthma
Session: Novel approaches in asthma
Session type: Oral Presentation
Number: 3267
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. B. Barnes, I. P. Pavord, A. C. Chuchalin, J. B. Bell, M. H. Hunter, M. P. Payton, L. P. C. Pearce Collins, R. P. Pettipher, J. S. Steiner, M. P. Perkins (London, Leicester, Oxford, United Kingdom; Moscow, Russian Federation). LATE-BREAKING ABSTRACT: A randomised, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 on moderate persistent asthma. Eur Respir J 2009; 34: Suppl. 53, 3267

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017


Late-breaking abstract: Inhaled pan-selectin antagonist bimosiamose in COPD: A double-blind, randomized, placebo-controlled phase II study
Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease
Year: 2011


A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis
Source: Eur Respir J 2015; 46: 1021-1032
Year: 2015



A randomized, double-blind, placebo-controlled study to evaluate the role of formoterol in management of acute asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 498s
Year: 2006

Late Breaking Abstract - Phase 2a randomised, double-blind, placebo-controlled, crossover study of a novel P2X3 receptor antagonist S-600918 in patients with refractory chronic cough
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough
Year: 2019




Omalizumab efficacy following cat allergen exposure: Results from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010


Airway hyperresponsiveness to mannitol as a predictor of treatment response to ciclesonide in patients with suspected asthma: A double-blind, randomised, placebo-controlled trial
Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease
Year: 2012

A randomised controlled trial of zafirlukast in acute asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 254s
Year: 2005

Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017


Methotrexate in treatment of severe difficult-to-treat asthma: randomized, double-blind, placebo-controlled study
Source: Annual Congress 2007 - Towards controlling severe asthma
Year: 2007


A randomized double-blind placebo-controlled trial on the short and long-term effects of electro acupuncture on moderate to severe asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 502s
Year: 2006

A double-blind double dummy randomised placebo-controlled cross-over design clinical trial of formoterol delivered by two different dry powder devices in prevention of bronchoconstriction induced by methacholine in mild to moderate persistent asthma in adult patients
Source: Annual Congress 2009 - Airway hyperresponsiveness: mechanism and assessment
Year: 2009

Umeclidinium in patients with COPD: a randomised, placebo-controlled study
Source: Eur Respir J 2014; 43: 72-81
Year: 2004



Nasal beclomethasone plus loratadine in patients with rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial
Source: Eur Respir J 2007; 30: Suppl. 51, 547s
Year: 2007

Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study
Source: Eur Respir J, 58 (5) 2004240; 10.1183/13993003.04240-2020
Year: 2021



Effects of a concomitant therapy with Cineole (Eucalyptole) on exacerbation rate in COPD: A placebo-controlled double-blind trial
Source: Annual Congress 2010 - COPD exacerbation
Year: 2010

Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011

Preventive effect of carbocysteine on exacerbation of asthma, GAIA randomised, placebo-controlled multi-centre study
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012


The use of modafinil in patients with obstructive apnoea-hyponoea syndrome (OAHS). A randomized, placebo-controlled, double-blind study
Source: Eur Respir J 2001; 18: Suppl. 33, 419s
Year: 2001

LATE-BREAKING ABSTRACT: Prevention of COPD exacerbation by lysozyme: A double-blind, randomized, placebo-controlled study
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015